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A mutational signature in gastric cancer suggests
therapeutic strategies
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Targeting defects in the DNA repair machinery of neoplastic cells, for example, those due to
inactivating BRCA1 and/or BRCA2 mutations, has been used for developing new therapies in
certain types of breast, ovarian and pancreatic cancers. Recently, a mutational signature was
associated with failure of double-strand DNA break repair by homologous recombination
based on its high mutational burden in samples harbouring BRCA1 or BRCA2 mutations. In
pancreatic cancer, all responders to platinum therapy exhibit this mutational signature
including a sample that lacked any defects in BRCA1 or BRCA2. Here, we examine 10,250
cancer genomes across 36 types of cancer and demonstrate that, in addition to breast,
ovarian and pancreatic cancers, gastric cancer is another cancer type that exhibits this
mutational signature. Our results suggest that 7–12% of gastric cancers have defective
double-strand DNA break repair by homologous recombination and may beneﬁt from either
platinum therapy or PARP inhibitors.
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G
ermline inactivating mutations in BRCA1 and/or BRCA2
cause an increased risk of early-onset breast1,2, ovarian2,3
and pancreatic cancer4, while somatic mutations in these
two genes and BRCA1 promoter hypermethylation have also been
implicated in development of these cancer types5,6. BRCA1 and
BRCA2 are involved in error-free homology directed double-
strand break repair7. Cancers with defects in BRCA1 and BRCA2
consequently show large numbers of rearrangements and indels
due to error-prone repair by non-homologous end joining
mechanisms, which assume responsibility for double-strand
break repair8,9.
While defective double-strand break repair increases the
mutational burden of a cell, thus increasing the chances of
acquiring somatic mutations that lead to neoplastic transforma-
tion, it also renders a cell more susceptible to cell cycle arrest and
subsequent apoptosis when it is exposed to agents such as
platinum-based antineoplastic drugs10,11. This susceptibility has
been successfully leveraged for the development of targeted
and less-toxic therapeutic strategies for treatment of breast,
ovarian and pancreatic cancers harbouring BRCA1 and/or
BRCA2 mutations, notably poly(adenosine diphosphate ribose)
polymerase (PARP) inhibitors10,11. These treatments cause a
multitude of DNA double-strand breaks that force neoplastic cells
with defective BRCA1 and BRCA2 function into apoptosis since
they lack the ability to effectively repair double-strand breaks. In
contrast, normal cells remain mostly unaffected since their repair
machinery is not compromised.
Exposure to exogenous or endogenous mutagens, abnormal
DNA editing, the incomplete ﬁdelity of DNA polymerases and
failure of DNA repair mechanisms generate distinct combinations
of somatic mutation types in cancer genomes12–14. We previously
termed such patterns ‘mutational signatures’ and developed an
approach for extracting mutational signatures from cancer
genomes15. Our previous analysis revealed 21 distinct base-
substitution signatures across the spectrum of human cancer12.
These base-substitution mutational signatures were described
using a simple classiﬁcation based on the six classes of single-base
mutations: C4A, C4G, C4T, T4A, T4C and T4G (all
substitutions are referred to by the pyrimidine of the mutated
Watson–Crick base pair) in combination with the base
immediately 50 and 30 to each mutation, thus resulting in 96
possible mutation types. Our previous analysis12 revealed that
cancers harbouring germline and/or somatic mutations in BRCA1
and BRCA2 exhibited a speciﬁc base-substitution signature,
termed signature 3. The mutational pattern of signature 3 is
shown in Fig. 1a. Interestingly, although almost all breast, ovarian
and pancreatic cancers with BRCA1/2 mutations have large
numbers of signature 3 mutations, a number of cancer cases
lacking mutations in BRCA1 and BRCA2 or other genes known to
play a role in double-strand break repair also exhibit the
mutational signature12. This observation hinted towards the
existence of other mechanisms that may be disabling homology
directed double-strand DNA break repair.
A recent clinical analysis of pancreatic whole-genome
sequencing data revealed that all samples responding to
platinum therapy exhibited substantial numbers of signature 3
mutations16. This therapeutic response was also observed in a
sample that lacked any germline or somatic BRCA1 or BRCA2
mutations, indicating that signature 3 itself could be used for
decision support in allocating these therapies, even in the absence
of BRCA1 or BRCA2 mutations.
In this study, we report a large-scale mutational signatures
analysis aiming to identify the presence of signature 3 across
human neoplasia. Our results reveal that, in addition to
previously known cancer types, signature 3 is also present in
7–12% of gastric cancers. These gastric cancers most likely have
defective homology directed double-strand DNA break repair and
may beneﬁt from either platinum therapy or PARP inhibitors.
Results
Large-scale survey of signature 3 across human neoplasia.
We used a substantially elaborated version of our previously
developed framework for deciphering mutational signatures
(Methods) and analysed 7,329,860 somatic mutations from
10,250 pairs of cancer-normal samples derived from 36 distinct
types of human cancer, including 607 whole-genome sequences
and 9,643 whole-exome sequences (Supplementary Data 1). As
expected, signature 3 was found in ovarian, breast and pancreatic
cancers (Fig. 1b; Supplementary Data 1). In ovarian cancer 143 of
the examined 466 ovarian whole exomes (B30.7% of ovarian
samples) exhibited signature 3. In breast cancer, signature 3 was
found in 283 of the 1,051 whole-exome breast cancer sequences
(B26.9%) and in 35 of the 119 whole-genome sequences
(B29.4%). Whole-genome sequencing of 15 pancreatic cancers
deliberately enriched for cases with BRCA1/2 mutations
revealed the presence of signature 3 in six samples (40.0%), while
examination of an unbiased set of 216 whole-exome sequenced
pancreatic cancers identiﬁed signature 3 in 16 cases (B7.41%).
Remarkably, despite surveying another 33 distinct cancer types
derived from diverse epithelial, mesenchymal, glial, haemato-
poietic and lymphoid cells, signature 3 was observed only in
gastric cancer. The examined data for gastric cancer included 372
whole-exome and 100 whole-genome sequences (Supplementary
Data 1). These data were derived from four independent
previously published studies17–20. We were able to detect
signature 3 in 27 whole exomes (B7.3% of the examined
whole-exome gastric samples) and in 12 whole-genomes (12.0%
of the examined whole-genome gastric samples). Some gastric
samples harboured BRCA1 or BRCA2 somatic mutations, but
there was no enrichment of signature 3 in samples with BRCA1/2
mutations. Most of these BRCA1/2 mutations were heterozygous
and were found in cases with a very high prevalence of small
indels and base substitutions due to defective DNA mismatch
repair and are, therefore, highly likely to be passenger mutations.
The contributions of all mutational signatures operative in the
examined set of gastric cancers are provided in Supplementary
Data 2, while the mutational signatures in the whole-genome-
sequenced samples are shown in Fig. 2. In addition, the genomic
proﬁles of two gastric samples harbouring signature 3 (one
sample with a BRCA2 mutation and another without a mutation
in either BRCA1 or BRCA2) are shown in Fig. 3.
Patterns of indels and structural rearrangements. The presence
of signature 3 mutations (and thus failure of DNA double-strand
repair by homologus recombination) is closely associated with a
particular pattern of large indels (longer than three base pairs)
with overlapping microhomology at the deletion break points in
breast, ovarian and pancreatic cancers. This pattern provides
additional evidence of the absence of homologous recombination-
based repair and the role of non-homologous end-joining
mechanisms. To evaluate further the signiﬁcance of ﬁnding
signature 3 mutations in gastric cancer, we searched for indels of
this type. Whole-genome sequenced gastric cancers harbouring
signature 3 had a median number of indels with overlapping
microhomologies at break points of 715 compared with a median
number of only 172 such indels in samples in which there was no
evidence for signature 3 (Supplementary Data 3; Mann–Whitney
U-test’s P value¼ 1.07 10 5). Similarly, gastric whole-exomes
exhibited a statistically signiﬁcant elevation of large indels with
overlapping microhomologies in samples in which signature 3
was found to be operative (Supplementary Data 4;
Mann–Whitney U-test’s P value¼ 5.87 10 4).
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Breast, ovarian and pancreatic cancers with BRCA1 or BRCA2
mutations and/or signature 3 mutations show larger numbers
of structural rearrangements than cases without, consistent
with a deﬁciency in error-free double-strand break repair.
We therefore compared the numbers of rearrangements in gastric
cancers with and without signature 3 mutations. Whole-genome
sequenced samples harbouring signature 3 had on average 244
structural variants versus 111 in samples that did not exhibit
signature 3 (Fig. 2; Supplementary Data 3; Mann–Whitney
U-test’s P value¼ 1.24 10 3). Thus, gastric cancers with
signature 3 mutations bear other mutational hallmarks of
failure of homology directed double-strand break repair, despite
the absence of inactivating mutations in BRCA1 and BRCA2
genes.
Association between signature 3 and gastric cancer histology.
Examining the histology of gastric samples with signature 3
revealed that they are enriched for the intestinal type by Lauren’s
classiﬁcation (Table 1; Fisher’s exact test’s P value¼ 5.80 10 3)
and have a tendency to display a distinctive compact discohesive
growth pattern that looks like ‘growth in cell suspension’
(Fig. 3b,c; Table 1; Fisher’s exact test’s P value¼ 3.00 10 4).
This pattern is characterized by solid nests of roundish malignant
cells with marked loss in cell-to-cell adhesion (Fig. 3b,c). These
nests are crowded together, which distinguishes them from
the diffuse-type gastric cancer with widely inﬁltrative growth
behaviour.
Presence of signature 3 in gastric cell lines. Our analysis of
10,250 primary cancers was also complemented by examination
of the generally available set of gastric cell lines to provide a
suitable model for testing the drug susceptibility of stomach
cancers harbouring signature 3. In total, we examined whole-
exome sequences of 20 gastric cell lines (Supplementary Data 5).
Unfortunately, we were not able to identify a cell line in which
signature 3 was present. This is perhaps unsurprising since the
5%
Mutation
type
probability
0%
Exome
Exome
Exome
Exome
Genome
Genome
Genome
0 10% 20% 30% 40%
40.0%
30.7%
29.3%
26.9%
Breast cancer
Ovarian cancer
Pancreatic cancer
Gastric cancer
7.4%
7.2%
12.0%
C > A C > G C > T T > A T > C T > G
Signature 3
Prevalence of signature 3 in cancer types
a
b
Figure 1 | Signature 3 and its presence in human cancer. (a) The mutational pattern of signature 3. The signature is displayed according to the
96 substitution classiﬁcation deﬁned by the substitution class and sequence context immediately 50 and 30 to the mutated base. The probability bars
for the six substitution classes are displayed in different colours. The mutation subtypes are on the x axis, and the y axis shows the percentage of mutations
in the signature attributed to each mutation type displayed on the basis of the trinucleotide frequencies of the whole human genome. (b) Prevalence of
signature 3 across human cancer types. The x axis depicts the percentage of samples in which signature 3 was observed. The y axis reﬂects the cancer
types in which signature 3 was observed as well as whether the data were derived via whole-genome or whole-exome sequencing. Note that the data set
did not have any ovarian whole-genome sequenced cancers. Further, it should be noted that the pancreatic whole-genome sequenced samples were
deliberately enriched with BRCA1/2 mutations explaining the high prevalence of signature 3.
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Figure 2 | The contributions of mutational signatures to individual gastric cancer whole-genome sequenced samples. Each bar represents a
whole-genome sequenced gastric cancer sample and is coloured proportionally to the number of somatic mutations contributed by each mutational
signature. The vertical axis denotes number of mutations per megabase. Signature 3 is coloured in red for clarity. ‘Other’ refers to mutational
signatures that have not been previously validated.
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20 cell lines lacked a matched-normal control, thus complicating
the detection of mutational signatures due to contamination with
high numbers of private germline polymorphisms.
Discussion
The results of this study provide the ﬁrst comprehensive large-
scale survey of mutational signature 3 across human cancer.
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Figure 3 | Two representative examples of gastric cancers harbouring signature 3 and their corresponding histology and genomic alterations.
(a,b) A gastric cancer with a BRCA2 somatic mutation (that is, pfg053T); (c,d) another gastric cancer without any known BRCA1 or BRCA2 mutations
(that is, pfg034T). In sections (a,d), the horizontal axes indicate chromosomal positions in ascending order. The top panel indicates somatic substitutions,
each dot represents a somatic mutation with their mutant fraction shown in the vertical axis. The bottom panel indicates variation in chromosome copy
number and structural variants. (b,c) Haematoxylin and eosin sections of gastric cancers, both showing compact sheets of malignant cells growing in
marked discohesive pattern. Scale bar, 100mm.
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It should be noted that most of the analysed 10,250 samples were
whole-exome sequenced (94% of samples) and it is possible that
our survey was not able to detect the presence of signature 3 in
cancer types and samples in which the signature generates
low numbers of somatic mutations. Nevertheless, our analysis
demonstrates that signature 3 is present inB7% of whole-exome
sequenced gastric cancers as well as 12% of whole-genome
sequenced gastric cancers. The results indicate that stomach
cancers with signature 3 mutations may have defective homology
directed double-strand DNA break repair.
Only very limited clinical data were available for the examined
gastric cancers restricting our opportunities for exploring
correlations between the presence of signature 3 with disease
progressions and outcome following treatment. Future studies,
involving larger cohorts of samples with carefully curated
clinically based data coupled with detailed histological data and
complimented by functional analysis, will be necessary to further
elaborate the connection between signature 3 and clinical
response in gastric cancer.
Gastric cancer is the second most common cause of
cancer-related deaths worldwide21. Since cancers with defective
homology directed double-strand break repair due to BRCA1 or
BRCA2 mutations are particularly sensitive to platinum therapy
and PARP inhibitors, it is conceivable that this subset of gastric
cancers might also beneﬁt from their usage. Current gastric
cancer chemotherapy protocols are variable and may include
5-ﬂuorouracil-based therapy only or in combination with
platinum-based drugs and other agents. Future precision
medicine clinical studies with a focus on patient selection will
be required to evaluate whether the presence of signature 3
substitutions, and the features of indels and rearrangements
associated with it, might allow better patient selection for
platinum-based drugs, and whether targeted therapies such as
PARP inhibitors based on defective DNA double-strand break
repair would also beneﬁt patients with gastric cancer.
Methods
Curation of freely available somatic mutations of cancer samples. No data
were generated speciﬁcally for the uses of this study. Rather, a large-scale data
curation was performed with the goal of annotating the majority of freely available
cancer genomes. Somatic mutations identiﬁed in 10,250 genome pairs (consisting
of a cancer genome and the genome of a matched normal tissue) were curated.
The curated data encompass 36 distinct types of cancer. In all, 607 of the 10,250
matched-normal pairs had their whole-genome sequenced, while the remaining
9,643 were subjected to whole-exome sequencing. Data were retrieved from three
main sources: (i) the data portal of The Cancer Genome Atlas, (ii) the data portal of
the International Cancer Genome Consortium and (iii) previously published data
in peer-reviewed journals. Information for each sample, including its original data
source, is provided in Supplementary Data 1. The somatic mutations for all
examined samples are freely available and can be retrieved based on the
information provided in Supplementary Data 1.
Filtering of somatic mutations and generating mutational catalogues. This
study relies on previously sequenced samples from cancer and normal tissues,
as well as from the subsequently used bioinformatics analyses to identify cancer
tissue-speciﬁc somatic mutations. The analysed sequencing data were originally
generated by a variety of different laboratories, leveraging different sequencing
platforms and using a diverse set of mutation-calling algorithms. To remove any
residual germline mutations as well as technology-, institute- and/or laboratory-
speciﬁc sequencing artefacts, extensive ﬁltering was performed before analysing the
data. Germline mutations were ﬁltered out from the lists of reported somatic
mutations using the complete list of germline mutations from dbSNP22, 1000
genomes project23, NHLBI GO Exome Sequencing Project24 and 69 Complete
Genomics panel (http://www.completegenomics.com/public-data/69-Genomes/).
Technology-speciﬁc sequencing artefacts were ﬁltered out by using panels of BAM
ﬁles of (unmatched) normal tissues containing more than 250 normal whole
genomes and 500 normal whole exomes. Any somatic mutation present in at least
two well-mapping reads in at least two normal BAM ﬁles was discarded. The
remaining somatic mutations constituted the mutational catalogue for every
matched-normal pair. The immediate 50 and 30 sequence context for each somatic
mutation was extracted using the ENSEMBL Core APIs for human genome build
GRCh37. Curated somatic mutations that originally mapped to an older version of
the human genome were re-mapped using UCSC’s freely available lift genome
annotations tool (https://genome.htseq.org/Bplantregulome/cgi-bin/hgLiftOver)25.
Any somatic mutations with ambiguous or missing mappings were discarded from
further analysis. The prevalence of somatic mutations in each sample was estimated
based on a haploid human genome after all ﬁltering was performed as previously
done in ref. 12.
Estimating the contributions of mutational signatures in each sample.
The mutational catalogues of all 10,250 samples were examined in two independent
and distinct steps. Initially, de novo extraction based on somatic substitutions
and their immediate sequence context was performed to derive the set of novel
consensus mutational signatures. Brieﬂy, mutational signatures were deciphered
independently for each of the 36 cancer types using our previously developed
computational MATLAB framework15. The computational framework for
deciphering mutational signatures is freely available (Supplementary Software 1)
and it can be also downloaded from: http://www.mathworks.com/matlabcentral/
ﬁleexchange/38724. The algorithm deciphers the minimal set of mutational
signatures that optimally explains the proportion of each mutation type found in
each catalogue and then estimates the contribution of each signature to each
mutational catalogue. Mutational signatures were also extracted separately for
genomes and exomes. Mutational signatures extracted from exomes were
normalized from the observed trinucleotide frequency in the human exome to the
trinucleotide frequency of the human genome. All mutational signatures were
clustered using unsupervised agglomerative hierarchical clustering and a threshold
was selected to identify the set of consensus mutational signatures. Misclustering of
signatures was avoided as previously described in ref. 12. A curated list of cancer
census mutational signatures and their presence in human cancer can be found at
our website: http://cancer.sanger.ac.uk/cosmic/signatures.
The de novo extraction was used to identify the complete set of consensus
mutational signatures across the examined 10,250 samples. The next step of the
analysis focused on accurately estimating the numbers of somatic mutations
associated with each mutational signature in each sample. We usually refer to this
Table 1 | Presence of signature 3 and gastric cancer histology.
Total samples Presence of signature 3 Fisher’s exact test’s two-tailed P value
Present (%) Absent (%)
Whole-genome sequencing cohort 100 12 (12.0) 88 (88.0)
Compact discohesive growth pattern 0.0003
Present 11 6 (54.5) 5 (45.5)
Absent 89 6 (6.7) 83 (93.3)
Whole-genome sequencing and TCGA cohorts combined 409 37 (9.0) 372 (91.0)
Laurens’ tumour type*
Intestinal 271 32 (11.8) 239 (88.2) 0.0058w
Diffuse 105 2 (1.9) 103 (98.1) 0.0015z
Mixed 33 3 (9.1) 30 (90.9)
TCGA, The Cancer Genome Atlas.
*Cases in the TCGA cohort without information on Laurens’ tumour type are excluded for analysis.
wIntestinal type versus diffuse type and mixed type.
zDiffuse type versus intestinal type and mixed type.
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number of somatic mutations as either the ‘contribution’ of a mutational signature
or the ‘exposure’ to a mutational signature. Calculating the contributions of all
mutational signatures was performed by estimating the number of mutations
associated with the consensus patterns of the signatures of all operative mutational
processes in each cancer sample. This approach allows direct comparison between
cancer types, because identical signatures were used to estimate the contributions
in each cancer type. More speciﬁcally, all consensus mutational signatures were
examined as a set P containing 33 vectors P¼
p11
..
.
p961
2
64
3
75;
p12
..
.
p962
2
64
3
75   
p132
..
.
p9632
2
64
3
75;
p133
..
.
p9633
2
64
3
75
8><
>:
9>=
>;
where each of the vectors is a discrete probability density function reﬂecting a
consensus mutational signature. The 96 non-negative components of each vector
correspond to the number of mutation types (that is, somatic substitutions and
their immediate sequencing context) of the consensus mutational signatures. The
contributions of the mutational signatures were estimated independently for each
of the 10,250 samples with a subset of consensus mutational signatures. For each
sample, the estimation algorithm consists of ﬁnding the minimum of the Frobenius
norm of a constrained linear function (see below for constraints) for a set of vectors
S1..q, qr33, belonging to the subset Q, where QDP (P is the hitherto mentioned set
encompassing all extracted consensus mutational signatures):
min M
!
Xq
i¼1
Si
!Ei
 

F
2
ð1Þ
The subset Q is determined based on the known operative mutational processes
in the cancer type of the examined sample from the mutational signature extraction
process described above. For example, for any neuroblastoma sample, Q will
contain signatures 1, 5 and 18, as these are the only known signatures of mutational
processes operative in neuroblastoma12. In equation (1), S
!
i and M
!
represent
vectors with 96 non-negative components (corresponding to the six somatic
substitutions and their immediate sequencing context) reﬂecting, respectively, a
consensus mutational signature and the mutational catalogue of the examined
sample. Hence, Si
!2 <96þ while M
!2 N960 . Further, both vectors have known
numerical values either from the de novo extraction (that is, S
!
i ) or from generating
the original mutational catalogue of the sample (that is, M
!
). In contrast, Ei
corresponds to an unknown scalar reﬂecting the number of mutations contributed
by signature S
!
i in the mutational catalogue M
!
.
Minimization of equation (1) is performed under several biologically
meaningful linear constraints. The set of vectors in the examined set Q is
constrained based on previously identiﬁed biological features of the consensus
mutational signatures. For example, consensus signature 6 causes high levels of
small insertions and/or deletions (indels) at mono/polynucleotide repeats12. Thus,
this mutational signature will be excluded from the set Q when the mutational
catalogue of an examined sample has only a few such indels. Similarly, there are
signatures associated with other types of indels, transcriptional strand bias,
dinucleotide mutations, hypermutator phenotypes and so on, and these signatures
are included in the set Q only when the sample in question exhibits one or more of
these features. Lists of features associated with different mutational signatures can
be found in ref. 12 as well as at our website: http://cancer.sanger.ac.uk/cosmic/
signatures. In addition to sample-speciﬁc constraints to the set Q, equation (1) was
universally constrained in regards to the parameter Ei. More speciﬁcally, the
number of somatic mutations contributed by a mutational signature in a sample
must be non-negative and it must not exceed the total number of somatic
mutations in that sample. Furthermore, the mutations contributed by all signatures
in a sample must equal the total number of somatic mutations of that sample.
These constraints can be mathematically expressed as 0  Ei  kSi!k1; i ¼ 1::q,
and
Pq
i¼1 Ei ¼kSi
!k1. The results for the contributions of mutational signature 3
in all 10,250 samples from the hitherto described approach are provided in
Supplementary Data 1.
Factors that inﬂuence extraction of mutational signatures. We have previously
used results from simulated data to describe a plethora of factors that inﬂuence the
accuracy of the extraction of mutational signatures15. Such factors include the
number of available samples, the number of somatic mutations in a sample, the
number of mutations contributed by different mutational signatures, the similarity
between the patterns of the signatures of mutational processes operative in cancer
samples, as well as the computational limitations of our framework. Nevertheless,
in the past 3 years, our framework has proven robust and has described multiple
similar and validated signatures across the spectrum of human cancer8,12,14,26–31.
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